TREATING DRY EYE DISEASE
Evaporation may impede the success of current DED treatments1,2
Current DED treatments, including lid hygiene, in-office procedures, and over-the-counter products, may help address MGD (meibomian gland dysfunction), a key upstream driver of excessive evaporation.3-6
Treatments may fall short in directly addressing tear
evaporation due to3-5:
Poor patient compliance
Suboptimal symptom relief
Patient discontinuation
Not all prescription eye drops for DED are the same7-11
Most Rx treatments leave excessive evaporation unaddressed.3,7-11
Anti-inflammatories and tear stimulators may be insufficient to resolve symptoms of DED, and low rates of compliance and adherence have been observed.12,13
In a retrospective insurance claim study of 6537 cyclosporine patients and 3235 lifitegrast patients,
with lifitegrast or cyclosporine
within 12 months12
Simply put, dry eye disease is the number one medical condition that motivates patients to see their ECP—and it will only grow.14
—Paul Karpecki, OD, FAAO
Evaporation can hinder treatment efforts, and addressing it may provide relief to more patients with DED1-3
If evaporation is not addressed, signs and symptoms of DED may chronically persist.15
Review select literature expanding on the
treatment of DED
Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye
White DE, et al.
Clin Ophthalmol. 2019
Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: proceedings of the OCEAN group meeting
Geerling G, et al.
Ocul Surf. 2017
Impact of dry eye disease on work productivity, and patients’ satisfaction with over-the-counter dry eye treatments
Nichols KK, et al.
Invest Ophthalmol Vis Sci. 2016
SIGN UP
Sign up to stay informed about dry eye disease (DED), find out what your peers think about managing DED, and get updates about the advancements that Bausch + Lomb is pursuing.
References: 1. Kim M, Lee Y, Mehra D, Sabater AL, Galor A. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. 2021;6(1):e000697. doi:10.1136/bmjophth-2020-000697 2. Dunn JD, Karpecki PM, Meske ME, Reissman D. Evolving knowledge of the unmet needs in dry eye disease. Am J Manag Care. 2021;27(2 suppl):S23-S32. doi:10.37765/ajmc.2021.88625 3. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802-812. doi:10.1016/j.jtos.2017.08.003 4. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050-2064. doi:10.1167/iovs.10-6997g 5. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628. doi:10.1016/j.jtos.2017.05.006 6. Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;300-306. doi:10.1136/bjophthalmol-2015-307415 7. Cequa. Prescribing information. Sun Pharmaceutical Industries, Inc; 2019. 8. Eysuvis. Prescribing information. Kala Pharmaceuticals; 2022. 9. Restasis. Prescribing information. Allergan; 2017. 10. Xiidra. Prescribing information. Novartis Pharmaceuticals Corporation; 2020. 11. Tyrvaya. Prescribing information. Oyster Point Pharmaceuticals; 2021. 12. White DE, Zhao Y, Ogundele A, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285-2292. doi:10.2147/OPTH.S226168 13. White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin Ophthalmol. 2020;14:875-883. doi:10.2147/OPTH.S233194 14. Karpecki P. The evolution of dry eye. Rev Optom. Published January 15, 2015. Accessed November 9, 2022. https://www.reviewofoptometry.com/article/the-evolution-of-dry-eye 15. Lienert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. Long-term natural history of dry eye disease from the patient's perspective. Ophthalmology. 2016;123(2):425-433. doi:10.1016/j.ophtha.2015.10.011
Follow Bausch + Lomb:
